Clinical trial · Interventional
A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL
A Phase 1/2, Open-Label, First-in-human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects With CD5+ Relapsed/Refractory T Cell Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Temporary operational pause; no safety concerns.
Summary
Brief summary (as posted)
This is a Phase 1/2 study to test the safety, tolerability, and efficacy of the investigational agent MT-101 in patients with T cell Lymphoma. MT-101 is made with myeloid cells collected from the patient's blood. The myeloid cells are modified and later infused back into their veins. The modified myeloid cells recognize the tumor cells and are designed to target and kill them.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adoptive Cellular Immunotherapy | — | UNRESOLVED | — |
| Cell Therapy | — | UNRESOLVED | — |
| Lymphoma, T-Cell, Cutaneous | Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Lymphoma, T-Cell, Peripheral | Lymphoma | ONTOLOGY_EXACT | 0.85 |
| Mycosis Fungoides | Mycosis Fungoides | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| MT-101 | Biological | — | UNRESOLVED |
| MT-101 + Conditioning (Lymphodepleting) Chemotherapy | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Cohort 1 and Cohort 3
- description
- MT-101
- interventionNames
- Biological: MT-101
- type
- EXPERIMENTAL
- label
- Cohort 2 and Cohort 4
- description
- MT-101 preceded by conditioning (lymphodepleting) chemotherapy
- interventionNames
- Other: MT-101 + Conditioning (Lymphodepleting) Chemotherapy
Primary outcomes (1)
- measure
- Safety and Tolerability of MT-101
- timeFrame
- 4 weeks
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Key Inclusion Criteria: * Adults age \> or equal to18 at the time the Informed Consent is signed * Refractory or relapsed pathologically confirmed T Cell Lymphoma (TCL): Peripheral T cell Lymphoma not otherwise specified (PTCL-NOS) , Angioimmunoblastic T cell Lymphoma (AITL), ALK-negative anaplastic large cell lymphoma (ALCL), ALK-positive ALCL, or Mycosis Fungoides (MF) stage IIB-IV including large cell transformation * CD5-expressing tumor by IHC or flow cytometry of tumor biopsy within 3 months of Screening or at Screening * Eastern Cooperative Oncology Group performance status \< 2 * Adequate organ function as defined in the protocol. Key Exclusion Criteria: * B1 and B2 disease (as defined in protocol for subjects with MF) * Known central nervous system involvement by PTCL * History of allogeneic transplant * History of intolerance to leukapheresis, plasmapheresis, or blood donation * Pregnant or nursing women * Any acute illness including fever (\> 100.4°F or \> 38°C), except fever related to tumor * Active systemic bacterial, fungal, or viral infection * Active chronic infection * Other primary malignancies, except adequately treated malignancies or complete remission * Active autoimmune disease that has required systemic therapy in the last 2 years * History of hemophagocytic lymphohistiocytosis * History of severe, immediate hypersensitivity reaction attributed to penicillin * Any other condition that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with the study requirements.
References
Publications (0)
Data not yet available